Cognition Therapeutics(CGTX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - Discussed plans to support a pivotal Alzheimer's disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - "Later this month we anticipate receiving the FDA's minutes from our end-of-Phase 2 meeting regarding registrational plans for zervimesine in Alzheimer's disease. We expect thes ...